The estimated Net Worth of Ryan M. Confer is at least $1.1 Milione dollars as of 28 July 2022. Mr. Confer owns over 116,973 units of Genprex Inc stock worth over $91,440 and over the last 6 years he sold GNPX stock worth over $0. In addition, he makes $1,004,400 as Chief Financial Officer at Genprex Inc.
Ryan has made over 1 trades of the Genprex Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 116,973 units of GNPX stock worth $2,339 on 28 July 2022.
The largest trade he's ever made was exercising 116,973 units of Genprex Inc stock on 28 July 2022 worth over $2,339. On average, Ryan trades about 14,622 units every 0 days since 2018. As of 28 July 2022 he still owns at least 190,499 units of Genprex Inc stock.
You can see the complete history of Mr. Confer stock trades at the bottom of the page.
Ryan M. Confer was Business Manager of the Company. From December 2013 through September 2016, he served as our Chief Operating and Financial Officer, and from June 2011 to December 2013 as our business Manager. Mr. Confer has served us in a variety of strategic, operations, and finance capacities since our inception in 2009 both as a consultant through his own firm, Confer Capital, Inc., and as an employee. Mr. Confer has over 10 years of entrepreneurial and executive experience in planning, launching, developing, and growing emerging technology companies. He has served in c-level and vice president roles for non-profit and for-profit entities since 2008. Most notably, Mr. Confer served as VP of Customer Experience and then later as VP of Strategy for KaiNexus Inc., an emerging technology company that develops continuous improvement software. Prior to his entrepreneurial experience, Mr. Confer served as a business development consultant for the University of Texas at Austin’s IC2 Institute, an international think tank and incubator, where he focused on evaluating the commercialization potential of nascent technologies in emerging growth markets. Mr. Confer holds a BS in finance and legal studies from Bloomsburg University of Pennsylvania and an MS in technology commercialization from the McCombs School of Business at the University of Texas at Austin.
As the Chief Financial Officer of Genprex Inc, the total compensation of Ryan Confer at Genprex Inc is $1,004,400. There are no executives at Genprex Inc getting paid more.
Ryan Confer is 38, he's been the Chief Financial Officer of Genprex Inc since 2016. There are 12 older and no younger executives at Genprex Inc. The oldest executive at Genprex Inc is William Wilson, 70, who is the Independent Director.
Ryan's mailing address filed with the SEC is 3300 BEE CAVE ROAD, #650-227, AUSTIN, TX, 78746.
Over the last 7 years, insiders at Genprex Inc have traded over $0 worth of Genprex Inc stock and bought 156,300 units worth $607,092 . The most active insiders traders include Ryan M. Confer, Christy M. Nance e Jack A Roth. On average, Genprex Inc executives and independent directors trade stock every 205 days with the average trade being worth of $14,575. The most recent stock trade was executed by John Rodney Varner on 21 April 2023, trading 19,000 units of GNPX stock currently worth $20,140.
genprex is mapping the future of cancer care. genprex's mission is to address the unmet medical needs of a growing population of cancer patients worldwide, through the development of a novel class of cancer drugs: immunogene therapy. our revolutionary clinical-stage products work synergistically with other approved and pipeline drugs to expand clinical indications for various cancers. about oncoprex® and lung cancer lung cancer is the second most common cancer in the u.s. but the leading cause of cancer death. there are approximately 225,000 new lung cancer cases in the u.s. per year and 1.8 million worldwide. the 5-year survival rate of stage iv non-small cell lung cancer (nsclc) is less than 1%, and treatment options beyond chemotherapy are lacking. approved nsclc targeted treatment options outside of chemo/radiation therapies only benefit a minority of patients. oncoprex® may now fill that gap by offering a targeted treatment option for a majority of nsclc patients. oncoprex® is cur
Genprex Inc executives and other stock owners filed with the SEC include: